Cyclooxygenase-2 Expression in Bladder Cancer and Patient Prognosis: Results from a Large Clinical Cohort and Meta-Analysis

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Czachorowski, Maciej J ^a   Amaral, André F S ^a   Montes Moreno, Santiago ^b   Lloreta, Josep ^c,d,e   Carrato, Alfredo ^f,g   Tardón, Adonina ^h   Morente, Manuel M ^a   Kogevinas, Manolis ⁱ   Real, Francisco X ^a,e   Malats, Núria ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e UNIVERSITAT POMPEU FABRA   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h UNIVERSITY OF OVIEDO   (Spain)

ⁱ CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CYCLOOXYGENASE 2; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS; TISSUE ARRAY ANALYSIS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84866401385     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045025     Document Type: Article

References (50)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Wu XR, (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5: 713-725.
3. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R, (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21: 1315-1330.
4. Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, et al. (2010) Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 70: 3463-3472.
5. Michaud DS, (2007) Chronic inflammation and bladder cancer. Urol Oncol 25: 260-268.
6. Fortuny J, Kogevinas M, Garcia-Closas M, Real FX, Tardon A, et al. (2006) Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol Biomarkers Prev 15: 1696-1702.
7. Daugherty SE, Pfeiffer RM, Sigurdson AJ, Hayes RB, Leitzmann M, et al. (2011) Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol 173: 721-730.
8. Harris RE, (2007) Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 42: 93-126.
9. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, et al. (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386.
10. Wheeler MA, Hausladen DA, Yoon JH, Weiss RM, (2002) Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer. J Urol 168: 1568-1573.
11. Shirahama T, (2000) Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 6: 2424-2430.
12. Aziz A, Lessard A, Moore K, Hovington H, Latulippe E, et al. (2010) Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2. BJU Int 108: 531-537.
13. Bamias A, Kyriakou F, Chorti M, Kavantzas N, Noni A, et al. (2008) Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study. Anticancer Res 28: 2479-2486.
14. Diamantopoulou K, Lazaris A, Mylona E, Zervas A, Stravodimos K, et al. (2005) Cyclooxygenase-2 protein expression in relation to apoptotic potential and its prognostic significance in bladder urothelial carcinoma. Anticancer Res 25: 4543-4549.
15. Eltze E, Wulfing C, Von Struensee D, Piechota H, Buerger H, et al. (2005) Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol 26: 1525-1531.
16. Friedrich MG, Toma MI, Petri S, Huland H, (2003) Cyclooxygenase-2 promotes angiogenesis in pTa/T1 urothelial bladder carcinoma but does not predict recurrence. BJU Int 92: 389-392.
17. Gudjonsson S, Bendahl PO, Chebil G, Hoglund M, Lindgren D, et al. (2011) Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer? Scand J Urol Nephrol 45: 270-277.
18. Hilmy M, Campbell R, Bartlett JM, McNicol AM, Underwood MA, et al. (2006) The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 95: 1234-1238.
19. Kim SI, Kwon SM, Kim YS, Hong SJ, (2002) Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 60: 816-821.
20. Liedberg F, Anderson H, Chebil G, Gudjonsson S, Hoglund M, et al. (2008) Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol 26: 17-24.
21. Margulis V, Shariat SF, Ashfaq R, Thompson M, Sagalowsky AI, et al. (2007) Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol 177: 1163-1168.
22. Mokos I, Jakic-Razumovic J, Marekovic Z, Pasini J, (2006) Association of cyclooxygenase-2 immunoreactivity with tumor recurrence and disease progression in superficial urothelial bladder cancer. Tumori 92: 124-129.
23. Naruse K, Yamada Y, Nakamura K, Aoki S, Taki T, et al. (2010) Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder. Oncol Rep 23: 1577-1583.
24. Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, et al. (2003) Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 169: 938-942.
25. Shariat SF, Matsumoto K, Kim J, Ayala GE, Zhou JH, et al. (2003) Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol 170: 985-989.
26. Shirahama T, Arima J, Akiba S, Sakakura C, (2001) Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 92: 188-193.
27. Tiguert R, Lessard A, So A, Fradet Y, (2002) Prognostic markers in muscle invasive bladder cancer. World J Urol 20: 190-195.
28. Wild PJ, Kunz-Schughart LA, Stoehr R, Burger M, Blaszyk H, et al. (2005) High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol 27: 385-391.
29. Wulfing C, Eltze E, von Struensee D, Wulfing P, Hertle L, et al. (2004) Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy. Eur Urol 45: 46-52.
30. Yoshimura R, Sano H, Mitsuhashi M, Kohno M, Chargui J, et al. (2001) Expression of cyclooxygenase-2 in patients with bladder carcinoma. J Urol 165: 1468-1472.
31. Youssef RF, Shariat SF, Kapur P, Kabbani W, Mosbah A, et al. (2011) Prognostic Value of Cyclooxygenase-2 Expression in Squamous Cell Carcinoma of the Bladder. J Urol 185: 6.
32. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, et al. (2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366: 649-659.
33. Epstein JI, Amin MB, Reuter VR, Mostofi FK, (1998) The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435-1448.
34. Mostofi F, Davis C, Sesterhen I (1999) Histological typing of urinary bladder tumours. World Health Organization international classification of histological tumours. Berlin: Springer Verlag.
35. Eble JN, Sauter G, Epstein JI, Sesterhen I (2004) Pathology and genetics of tumours of the urinary system and male genital organs. WHO classification of tumours. Lyon, France IARC Press.
36. Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, et al. (2010) A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 16: 637-650.
37. Metz CE, (1978) Basic principles of ROC analysis. Semin Nucl Med 8: 283-298.
38. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
39. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
40. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
41. Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Amoros A, et al. (2006) Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24: 3664-3671.
42. Lopez-Knowles E, Hernandez S, Kogevinas M, Lloreta J, Amoros A, et al. (2006) The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 12: 6029-6036.
43. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391.
44. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med 3: e123-e130.
45. Ristimaki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, et al. (2001) Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 158: 849-853.
46. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, et al. (1999) Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59: 5647-5650.
47. Komhoff M, Guan Y, Shappell HW, Davis L, Jack G, et al. (2000) Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 157: 29-35.
48. Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Moller S, Ejlertsen B, et al. (2007) Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 60: 397-404.
49. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436-444.
50. Ferrandina G, Lauriola L, Zannoni GF, Distefano MG, Legge F, et al. (2002) Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. Br J Cancer 87: 1145-1152.